In the four-arm study, 514 patients undergoing cataract surgery at 47 clinical sites across the US were randomised to receive either sub-micron loteprednol etabonate ophthalmic gel (0.
According to the company, the new gel formulation features a sub-micron particle size to enhance tissue penetration of the drug and a lower concentration of loteprednol etabonate (0.
Prednisolone acetate 1% was discontinued and loteprednol etabonate
The corticosteroid component of Zylet is loteprednol etabonate
, Bausch & Lomb's proven, patented, site-specific steroid, which, for the first time, is combined with the time-tested efficacy of tobramycin to be the first novel ophthalmic corticosteroid/antibiotic combination approved by FDA in more than 15 years.
The product under FDA review is a loteprednol etabonate and tobramycin ophthalmic suspension (0.
In 2001, Bausch & Lomb acquired the rights to the loteprednol etabonate ophthalmic business of Pharmos Corporation.
L) announced today the initiation of a phase III trial of loteprednol etabonate
for the treatment of allergic rhinitis.
Bausch & Lomb (NYSE: BOL) announces the acquisition of all rights to the loteprednol etabonate
ophthalmic business of Pharmos Corporation (Nasdaq: PARS and Nasdaq Europe: PHRM) for cash and assumption of certain ongoing obligations.
L) announced today it has acquired the worldwide rights for the dermatological use of loteprednol etabonate
(LE), a new "soft" corticosteroid to treat dermatological conditions, and plans to shortly start Phase II clinical trials to demonstrate its safety and efficacy.
Bausch & Lomb is the leading global technology-based healthcare company for the eye, and Pharmos' marketing partner for its loteprednol etabonate
The advantages of a Lotemax(TM)/tobramycin combination product lie in the favorable safety and efficacy profile of Loteprednol etabonate
, the active ingredient in Lotemax, which is expected to be preferred by practitioners over other ocular corticosteroids.
BUSINESS WIRE)--June 10, 1996--PHARMOS CORPORATION (NASDAQ: PARS) today announced that it has completed two Phase III clinical trials for the first of two line extension products, with the Company's proprietary compound loteprednol etabonate
for the treatment of ocular allergies.